Adani a été classé le plus important propriétaire de centrales solaires au monde
September 01, 2020 17:36 ET
|
Adani Green Energy
Son portefeuille mondial de 12,32 GWac dépasse la capacité totale installée de l'ensemble du secteur solaire aux États-Unis en 2019 SYNOPSIS Mercom Capital classe Adani Group au premier rang...
Adani ranked as the largest solar power generation owner in the world
September 01, 2020 07:00 ET
|
Adani Green Energy
EDITOR’S SYNOPSIS Mercom Capital ranks the Adani Group as the #1 global solar power generation asset ownerAdani’s portfolio is 12.32 GWac which exceeds total installed capacity of U.S. in 2019Adani’s...
Adani Green Energy erhält Zuschlag für weltweit größten Solarauftrag und nähert sich damit seinem Ziel einer installierten Kapazität von 25 GW bis 2025
June 09, 2020 23:10 ET
|
Adani Green Energy
DALLAS, June 10, 2020 (GLOBE NEWSWIRE) -- Adani Green Energy Limited (AGEL, NSE: ADANIGREEN) hat den Zuschlag für eine erstmalig in dieser Form ausgeschriebene Fertigungsvereinbarung für...
Adani Green Energy remporte le plus grand contrat solaire au monde ; l'entreprise se rapproche ainsi considérablement de l'objectif de 25 GW de capacité installée d'ici 2025
June 09, 2020 23:10 ET
|
Adani Green Energy
DALLAS, 10 juin 2020 (GLOBE NEWSWIRE) -- Adani Green Energy Limited (AGEL, NSE : ADANIGREEN) a remporté le premier contrat de fabrication solaire en son genre auprès de Solar Energy Corporation of...
Adani Green Energy wins the world’s largest solar award; Leapfrogs towards goal of 25 GW of installed capacity by 2025
June 09, 2020 02:15 ET
|
Adani Green Energy
DALLAS, June 09, 2020 (GLOBE NEWSWIRE) -- Adani Green Energy Limited (AGEL, NSE: ADANIGREEN) has won the first of its kind manufacturing linked solar agreement from the Solar Energy Corporation of...
US FDA Grants Mexiletine Orphan Drug Designation
June 08, 2020 01:03 ET
|
Lupin Ltd
US FDA Grants Mexiletine Orphan Drug Designation Zug, Switzerland, 8 June 2019: Lupin is pleased to announce that the US Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD)...
Lupin signs distribution agreements in key EU territories for orphan drug NaMuscla®
June 03, 2020 01:00 ET
|
Lupin Ltd
Lupin signs distribution agreements in key EU territories for orphan drug NaMuscla®Enables expanded patient access of rare disease medicine to treat myotonia symptoms in non-dystrophic myotonic...
Lupin Announces Launch of Orphan Drug NaMuscla® in Germany and the UK for the Treatment of Myotonia in Non-Dystrophic Myotonic Disorders
February 01, 2019 05:04 ET
|
Lupin Ltd
Lupin Announces Launch of Orphan Drug NaMuscla® in Germany and the UK for the Treatment of Myotonia in Non-Dystrophic Myotonic Disorders Zug, Switzerland, 1 February 2019: Lupin is pleased to...
Lupin Limited: Orphan Drug NaMuscla® Receives European Commission Approval for the Treatment of Myotonia in Non-Dystrophic Myotonic Disorders
January 08, 2019 00:00 ET
|
Lupin Neurosciences Ltd
Orphan Drug NaMuscla® Receives European Commission Approval for the Treatment of Myotonia in Non-Dystrophic Myotonic Disorders Zug, Switzerland, 8 January 2019: Lupin is pleased to announce that the...
Lupin Neurosciences Announces Positive CHMP Opinion for NaMuscla™ for the Treatment of Myotonia in Non-Dystrophic Myotonic Disorders
October 19, 2018 07:44 ET
|
Lupin Neurosciences Ltd
Lupin Neurosciences Announces Positive CHMP Opinion for NaMuscla™ for the Treatment of Myotonia in Non-Dystrophic Myotonic Disorders Zug, Switzerland, October 19, 2018: Lupin Neurosciences, a...